EGFR positive
Showing 1 - 25 of >10,000
CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)
Active, not recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- EGFR806-specific chimeric antigen receptor (CAR) T cell
-
Seattle, WashingtonSeattle Children's Hospital
Jan 18, 2023
Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
Recruiting
- Lung Cancer Non-small Cell Stage IV
-
Athens, GreeceHellenic Cooperative Oncology Group
Nov 14, 2022
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
NSCLC, NSCLC Trial in Miami, Cleveland (Osimertinib)
Active, not recruiting
- NSCLC
- Non-small Cell Lung Cancer
-
Miami, Florida
- +1 more
Nov 8, 2022
Solid Tumor, Adult, EGFR Overexpression Trial in Beijing (TGFßR-KO CAR-EGFR T Cells)
Recruiting
- Solid Tumor, Adult
- EGFR Overexpression
- TGFβR-KO CAR-EGFR T Cells
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Mar 25, 2022
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Duarte, New Haven (procedure, drug, radiation, other)
Not yet recruiting
- Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
-
Duarte, California
- +1 more
Aug 24, 2023
Advanced EGFR Positive Solid Tumor Trial in China, United States (ZZ06)
Recruiting
- Advanced EGFR Positive Solid Tumor
- ZZ06
-
Los Angeles, California
- +3 more
Mar 7, 2022
Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
- concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
-
Jerusalem, IsraelShaare Zedek Medical Center
Jan 22, 2023
Osimertinib for Advanced EGFR-positive NSCLC Patients
Recruiting
- EGFR Positive Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
-
Singapore, SingaporeNational University Hospital
Aug 31, 2021
Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,
Recruiting
- Lung Cancer, Non-small Cell
- +4 more
- Genomic profiles detection
- circulating tumor DNA detection
-
Changsha, Hunan, ChinaDepartment of Oncology, The Second Xiangya Hospital, Central Sou
Oct 25, 2022
Lung Cancer, Colorectal Cancer Trial in Saskatoon (50 mg 89Zr-DFO-Nimotuzumab, 1 mg 89Zr-DFO-Nimotuzumab)
Recruiting
- Lung Cancer
- Colorectal Cancer
- 50 mg 89Zr-DFO-Nimotuzumab
- 1 mg 89Zr-DFO-Nimotuzumab
-
Saskatoon, Saskatchewan, CanadaRoyal University Hospital
May 18, 2022
NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Befotertinib + Icotinib placebo
- Icotinib + Befotertinib placebo
-
Beijing, China
- +2 more
Sep 20, 2023
NSCLC Trial (Almonertinib Envafolimab)
Not yet recruiting
- Non-small Cell Lung Cancer
- Almonertinib Envafolimab
- (no location specified)
Sep 10, 2022
NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)
Recruiting
- Non-small Cell Lung Cancer Stage III
- +2 more
-
Busan, Korea, Republic of
- +12 more
Jan 17, 2023
EGFR Positive NSCLC Trial in Goyang-Si (Erlotinib plus Bevacizumab, Erlotinib)
Active, not recruiting
- EGFR Positive Non-small Cell Lung Cancer
- Erlotinib plus Bevacizumab
- Erlotinib
-
Goyang-Si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Mar 23, 2023
Central Nervous System Metastatic EGFR Mutation Positive NSCLC
Not yet recruiting
- NSCLC
-
Changsha, Hunan, ChinaHunan Cancer hospital
Aug 6, 2023
NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)
Active, not recruiting
- NSCLC Stage IIIB
- +4 more
-
Hong Kong, Hong Kong
- +8 more
Jan 10, 2023
NSCLC Trial in Shanghai (TY-9591(10mg,40mg) qd. po)
Recruiting
- NSCLC
- TY-9591(10mg,40mg) qd. po
-
Shanghai, ChinaShanghai Chest Hospital
Nov 7, 2021
EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer Trial in Guangzhou
Recruiting
- EGFR/ B7H3-positive Advanced Lung Cancer
- EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
- EGFR/B7H3 CAR-T
-
Guangzhou, Guangdong, ChinaSecond Affiliated Hospital of Guangzhou Medical University
Apr 18, 2022
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)
Recruiting
- Lung Adenocarcinoma Stage III
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Aug 13, 2022